LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Immunic Inc.
Headquarters:
New York, NY, United States of America
Website:
https://imux.com/
Year Founded:
2016
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Daniel Vitt, PhD
Number Of Employees:
77
Enterprise Value:
$21,140,075
PE Ratio:
-0.9
Exchange/Ticker 1:
NASDAQ:IMUX
Exchange/Ticker 2:
N/A
Latest Market Cap:
$100,888,496
BioCentury
|
Jul 10, 2024
Management Tracks
Promotions for Flagship’s Afzelius, Biondi come amid $3.6B raise
Plus: EveryONE names CEO and chairman and updates from Lunit, Quell, ImCheck, Aktis, Immunic and Curve
Read More
BioCentury
|
Feb 20, 2024
Distillery Therapeutics
Inhibiting epithelial SIRT6 for asthma
Read More
BioCentury
|
Jan 6, 2024
Finance
Jan. 5 Quick Takes: Metagenomi, ArriVent file for IPO
Plus: Immunic eyes $240M private placement and updates from Applied Therapeutics and Novartis
Read More
BioCentury
|
Oct 21, 2022
Politics, Policy & Law
Oct. 20 Quick Takes: Novartis commits first cancer therapy to UN patent pool
Plus: AbbVie gains LPAR1 antibody via $255M buy of DJS and updates for Denali, the U.K., Kite-Refuge, Takeda-Zedira, Immunic, Talaris, Celeris
Read More
BioCentury
|
Jun 3, 2022
Deals
June 2 Quick Takes: BMS, Immatics expand partnership to allogeneic T cells
Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more
Read More
BioCentury
|
Mar 17, 2022
Management Tracks
Denali co-founder, COO Schuth to take on CFO role
Plus Immunic promotes Whaley to CFO and updates from Mablink, Agendia, SNIPR and more
Read More
BioCentury
|
Oct 15, 2021
Management Tracks
Malek joins NIBR as head of oncology disease area
Plus: Translate Bio vet Smith joins CRISPR as CFO and updates from Travere, Kojin, AMO, Poseida, Synairgen and more
Read More
BioCentury
|
Aug 4, 2020
Product Development
Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more
Read More
BioCentury
|
Jun 12, 2020
Finance
May’s momentum continues as Catalent, eight others price follow-ons
Read More
BioCentury
|
May 15, 2020
Product Development
Repurposed autoimmune therapies head for controlled COVID-19 studies in Europe
Plus USPTO to fast-track patent reviews, and a social distancing tool for the lab and office
Read More
Items per page:
10
1 - 10 of 19